End-of-day quote
Shanghai S.E.
06:00:00 2024-05-27 pm EDT
|
5-day change
|
1st Jan Change
|
2.76
CNY
|
-4.83%
|
|
-7.69%
|
-64.29%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
3,376
|
3,164
|
5,055
|
4,949
|
7,227
|
4,538
|
Enterprise Value (EV)
1 |
2,442
|
2,826
|
4,842
|
4,750
|
7,062
|
4,380
|
P/E ratio
|
47.8
x
|
539
x
|
-15.9
x
|
-20.1
x
|
-25.1
x
|
-16.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.1
x
|
13.5
x
|
40.7
x
|
38.7
x
|
45.1
x
|
21.2
x
|
EV / Revenue
|
7.33
x
|
12.1
x
|
39
x
|
37.2
x
|
44.1
x
|
20.5
x
|
EV / EBITDA
|
-185
x
|
-150
x
|
-48.4
x
|
-28
x
|
-42
x
|
-44.1
x
|
EV / FCF
|
-13.6
x
|
12.6
x
|
-20.1
x
|
-56.7
x
|
127
x
|
66.9
x
|
FCF Yield
|
-7.36%
|
7.91%
|
-4.98%
|
-1.76%
|
0.79%
|
1.49%
|
Price to Book
|
1.42
x
|
1.32
x
|
2.44
x
|
2.72
x
|
4.71
x
|
3.59
x
|
Nbr of stocks (in thousands)
|
588,075
|
587,061
|
587,061
|
587,061
|
587,061
|
587,061
|
Reference price
2 |
5.740
|
5.390
|
8.610
|
8.430
|
12.31
|
7.730
|
Announcement Date
|
4/18/19
|
4/29/20
|
4/29/21
|
4/25/22
|
4/28/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
333
|
233.7
|
124.3
|
127.8
|
160.2
|
213.9
|
EBITDA
1 |
-13.22
|
-18.81
|
-100
|
-169.7
|
-168.2
|
-99.28
|
EBIT
1 |
-54.04
|
-57.48
|
-139.7
|
-209.9
|
-207.7
|
-119.8
|
Operating Margin
|
-16.23%
|
-24.59%
|
-112.43%
|
-164.28%
|
-129.7%
|
-56.02%
|
Earnings before Tax (EBT)
1 |
63.65
|
-1.722
|
-315
|
-252.5
|
-295.3
|
-260.3
|
Net income
1 |
68.45
|
5.808
|
-319.5
|
-248.6
|
-287.5
|
-267.9
|
Net margin
|
20.55%
|
2.48%
|
-257.14%
|
-194.59%
|
-179.52%
|
-125.24%
|
EPS
2 |
0.1200
|
0.0100
|
-0.5400
|
-0.4200
|
-0.4900
|
-0.4600
|
Free Cash Flow
1 |
-179.7
|
223.5
|
-241.1
|
-83.72
|
55.74
|
65.48
|
FCF margin
|
-53.96%
|
95.6%
|
-194.04%
|
-65.53%
|
34.8%
|
30.61%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
3,847.49%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/18/19
|
4/29/20
|
4/29/21
|
4/25/22
|
4/28/23
|
4/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
933
|
338
|
213
|
198
|
164
|
158
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-180
|
223
|
-241
|
-83.7
|
55.7
|
65.5
|
ROE (net income / shareholders' equity)
|
2.92%
|
0.24%
|
-14.3%
|
-12.8%
|
-17.1%
|
-19%
|
ROA (Net income/ Total Assets)
|
-1.39%
|
-1.48%
|
-3.78%
|
-6.47%
|
-7.62%
|
-5.13%
|
Assets
1 |
-4,934
|
-391.6
|
8,444
|
3,842
|
3,773
|
5,220
|
Book Value Per Share
2 |
4.050
|
4.070
|
3.520
|
3.100
|
2.610
|
2.150
|
Cash Flow per Share
2 |
0.5300
|
0.4700
|
0.3100
|
0.2800
|
0.2900
|
0.2900
|
Capex
1 |
43.5
|
5.29
|
198
|
122
|
0.82
|
13.5
|
Capex / Sales
|
13.07%
|
2.26%
|
159.04%
|
95.33%
|
0.51%
|
6.33%
|
Announcement Date
|
4/18/19
|
4/29/20
|
4/29/21
|
4/25/22
|
4/28/23
|
4/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -64.29% | 224M | | +42.07% | 6.23B | | -21.20% | 4.19B | | +5.38% | 3.32B | | -16.98% | 2.91B | | -5.82% | 2.42B | | +45.47% | 1.94B | | -12.67% | 1.59B | | -3.91% | 1.58B | | +44.56% | 1.49B |
Alternative Medicine
|